• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Immunic Inc. (Amendment)

    2/14/24 4:05:39 PM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMUX alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

    Immunic, Inc.

     

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

     

    (Title of Class of Securities)

     

    4525EP101

     

    (CUSIP Number)

     

    December 31, 2023

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 4525EP101   SCHEDULE 13G    

     

    1

    NAME OF REPORTING PERSONS

     

    Commodore Capital LP

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware, USA

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ☐

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.0%

    12

    TYPE OF REPORTING PERSON

     

    IA

     

     

     

     

    CUSIP No. 4525EP101   SCHEDULE 13G    

     

    1

    NAME OF REPORTING PERSONS

     

    Commodore Capital Master LP

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ☐

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.0%

    12

    TYPE OF REPORTING PERSON

     

    OO

     

     

     

     

    CUSIP No. 4525EP101   SCHEDULE 13G    

     

    Item 1. (a) Name of Issuer

     

    Immunic, Inc. (the “Issuer”)

     

    Item 1. (b) Address of Issuer’s Principal Executive Offices

     

    1200 Avenue of the Americas, Suite 200, New York, New York 10036

     

    Item 2. (a, b, c) Names of Person Filing, Address of Principal Business Office, Citizenship:

     

    This report on Schedule 13G is being filed by Commodore Capital LP, a Delaware limited partnership (the “Firm”) and Commodore Capital Master LP, a Cayman Islands exempted limited partnership (“Commodore Master”). The address for the Firm and Commodore Master is: 444 Madison Avenue, Floor 35, New York, New York 10022.

     

    Item 2. (d) Title of Class of Securities

     

    Common Stock, par value $0.0001 per share (the “Common Stock”)

     

    Item 2. (e) CUSIP No.:

     

    4525EP101

     

    Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person filing is a:

     

    N/A

     

     

     

     

    CUSIP No. 4525EP101   SCHEDULE 13G    

     

    Item 4. Ownership

     

    As reported in the cover pages to this report, the ownership information with respect to the Firm is as follows:

     

      (a) Amount Beneficially Owned: 0
         
      (b) Percent of Class: 0.0%
         
      (c) Number of Shares as to which such person has:

     

        (i) Sole power to vote or to direct the vote: 0
           
        (ii) Shared power to vote or to direct the vote: 0
           
        (iii) Sole power to dispose or to direct the disposition of: 0
           
        (iv) Shared power to dispose or to direct the disposition of: 0

     

    As reported in the cover pages to this report, the ownership information with respect to Commodore Master is as follows:

     

      (a) Amount Beneficially Owned: 0
         
      (b) Percent of Class: 0.0%
         
      (c) Number of Shares as to which such person has:

     

        (i) Sole power to vote or to direct the vote: 0
           
        (ii) Shared power to vote or to direct the vote: 0
           
        (iii) Sole power to dispose or to direct the disposition of: 0
           
        (iv) Shared power to dispose or to direct the disposition of: 0

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

     

    Not Applicable.

     

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not Applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not Applicable.

     

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Exhibit Index

     

      1. Joint Filing Agreement dated as of October 21, 2022, by and between Commodore Capital LP and Commodore Capital Master LP (incorporated by reference to Exhibit 1 to the Schedule 13G filed with the Securities and Exchange Commission on October 21, 2022).

     

     

     

     

    CUSIP No. 4525EP101   SCHEDULE 13G    

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024

     

    Commodore Capital LP  
         
    By: /s/ Michael Kramarz  
      Michael Kramarz, Managing Partner  
         
    Commodore Capital Master LP  
         
    By: /s/ Michael Kramarz  
      Michael Kramarz, Authorized Signatory  

     

     

    Get the next $IMUX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMUX

    DatePrice TargetRatingAnalyst
    3/25/2025Outperform
    William Blair
    11/25/2024$10.00Buy
    H.C. Wainwright
    9/9/2024$5.00Outperform
    Leerink Partners
    8/27/2024$6.00Buy
    B. Riley Securities
    10/21/2022$5.00Outperform → Mkt Perform
    SVB Leerink
    9/19/2022$26.00Buy
    H.C. Wainwright
    9/7/2021$40.00 → $25.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $IMUX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS

      – Enrollment Completed for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected End of 2026 – – Additional Data from Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis Further Supports the Recently Released Positive Top-Line Results and Further Underlines Vidofludimus Calcium's Neuroprotective Potential – – New CALLIPER Data Regarding Time to 24-Week Confirmed Disability Worsening Shows Substantial and Medically Relevant Reductions for Vidofludimus Calcium Over Placebo in the Overall Study Population and Major Disease Subtypes – NEW YORK, June 5, 2025 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a

      6/5/25 6:30:00 AM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

      NEW YORK, June 3, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the closing of its previously announced underwritten public offering of (i) pre-funded warrants to purchase shares of common stock (the "Pre-Funded Warrants"), (ii) series A warrants to purchase shares of common stock (or pre-funded warrants) (the "Series A Warrants"), and (iii) series B warrants to purchase shares of common stock (or pre-funded warrants) (the "Series B Warrants"). The Pre-Funded Warrants are immediately exercisa

      6/3/25 4:01:00 PM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunic to Participate in Investor, Scientific and Industry Conferences in June

      NEW YORK, June 2, 2025 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor, scientific and industry conferences in June: June 3-5: Jefferies Healthcare Conference. Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will present a company overview on Thursday, June 5, 2025 at 4:55 pm ET at this conference in New York. A webcast will be available on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations.Dr. Vitt, Jason Tardio, President

      6/2/25 6:30:00 AM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMUX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Immunic

      William Blair initiated coverage of Immunic with a rating of Outperform

      3/25/25 8:27:26 AM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Immunic with a new price target

      H.C. Wainwright initiated coverage of Immunic with a rating of Buy and set a new price target of $10.00

      11/25/24 7:45:37 AM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners resumed coverage on Immunic with a new price target

      Leerink Partners resumed coverage of Immunic with a rating of Outperform and set a new price target of $5.00

      9/9/24 7:37:13 AM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMUX
    Financials

    Live finance-specific insights

    See more

    $IMUX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $IMUX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

      – 24-Week Data from First Half of Patients Shows Improvements in Biomarker NfL, Consistent Throughout the Overall Progressive Multiple Sclerosis Population as well as All Subtypes – – NfL Effect in Non-Active Subpopulation Reinforces Vidofludimus Calcium's Neuroprotective Potential – – Brain Volume Data of the Full 467 CALLIPER Patient Cohort Expected in April 2025 – – Phase 3 ENSURE Program in Relapsing Multiple Sclerosis Ongoing – – Conference Call and Webcast to be Held Tomorrow, October 10, 2023 at 8:00 am ET – NEW YORK, Oct. 9, 2023 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chr

      10/9/23 4:01:00 PM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders

      – Positive Effects Demonstrated Over Placebo in Four Key Dimensions of Celiac Disease Pathophysiology: Protection of Gut Architecture, Improvement of Patients' Symptoms, Biomarker Response, and Enhancement of Nutrient Absorption – – Corroborates Hypothesized Ability of IMU-856 to Renew Gut Wall and Restore Gut Health – – No Safety or Tolerability Issues Detected – – Conference Call and Webcast to be Held Today, May 4, 2023 at 8:00 am ET – NEW YORK, May 4, 2023 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced positive results fro

      5/4/23 6:30:00 AM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis

      – 50-Week Maintenance Phase Data Shows Dose-Linear Increase in Clinical Remission for Vidofludimus Calcium as Compared to Placebo – – 30 mg Once-Daily Dose of Vidofludimus Calcium Demonstrated Statistically Significant Rates of Clinical Remission (p=0.0358) and Endoscopic Healing (p=0.0259) at Week 50 – – To Focus Resources on High Performing Vidofludimus Calcium and IMU-856 Programs, Immunic Decided to Deprioritize Izumerogant (IMU-935) Program – – Conference Call and Webcast to be Held today, April 5, 2023 at 8:00 am ET – NEW YORK, April 5, 2023 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapi

      4/5/23 6:30:00 AM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Neermann Joerg bought $76,700 worth of shares (100,000 units at $0.77), increasing direct ownership by 100% to 200,000 units (SEC Form 4)

      4 - IMMUNIC, INC. (0001280776) (Issuer)

      6/5/25 4:07:04 PM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Whaley Glenn was granted 25,000 shares and bought $32,076 worth of shares (45,000 units at $0.71), increasing direct ownership by 274% to 95,510 units (SEC Form 4)

      4 - IMMUNIC, INC. (0001280776) (Issuer)

      6/4/25 4:22:22 PM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Rudick Richard Alan bought $100,024 worth of shares (143,075 units at $0.70), increasing direct ownership by 164% to 230,375 units (SEC Form 4)

      4 - IMMUNIC, INC. (0001280776) (Issuer)

      6/4/25 4:06:00 PM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Immunic Inc.

      SC 13G/A - IMMUNIC, INC. (0001280776) (Subject)

      11/14/24 5:33:45 PM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Immunic Inc.

      SC 13G/A - IMMUNIC, INC. (0001280776) (Subject)

      11/14/24 12:30:35 PM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Immunic Inc.

      SC 13G/A - IMMUNIC, INC. (0001280776) (Subject)

      11/14/24 6:58:13 AM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMUX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Neermann Joerg bought $76,700 worth of shares (100,000 units at $0.77), increasing direct ownership by 100% to 200,000 units (SEC Form 4)

      4 - IMMUNIC, INC. (0001280776) (Issuer)

      6/5/25 4:07:04 PM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Whaley Glenn was granted 25,000 shares and bought $32,076 worth of shares (45,000 units at $0.71), increasing direct ownership by 274% to 95,510 units (SEC Form 4)

      4 - IMMUNIC, INC. (0001280776) (Issuer)

      6/4/25 4:22:22 PM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Rudick Richard Alan bought $100,024 worth of shares (143,075 units at $0.70), increasing direct ownership by 164% to 230,375 units (SEC Form 4)

      4 - IMMUNIC, INC. (0001280776) (Issuer)

      6/4/25 4:06:00 PM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMUX
    SEC Filings

    See more
    • Immunic Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - IMMUNIC, INC. (0001280776) (Filer)

      6/4/25 4:07:37 PM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunic Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - IMMUNIC, INC. (0001280776) (Filer)

      5/30/25 4:44:33 PM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Immunic Inc.

      424B5 - IMMUNIC, INC. (0001280776) (Filer)

      5/30/25 4:43:09 PM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMUX
    Leadership Updates

    Live Leadership Updates

    See more
    • Immunic Highlights 2024 Accomplishments and Upcoming Milestones

      – Top-Line Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in April – – Reported Positive Outcome from Interim Analysis of Ongoing, Twin Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Both Trials on Track to Be Completed in 2026 – – Strengthened Management Team and Board of Directors with Key Hires – – Announced a Three-Tranche Private Placement Totaling Up to $240 Million, Extending Cash Runway Into the Third Quarter of 2025, Based on Initial $80 Million Tranche – NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered,

      1/7/25 6:30:00 AM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec

      – Senior Executive and Thought Leader in Brain Health with Nearly Three Decades of Global Pharmaceutical Experience – – Served as Neuroimmunology Franchise Head Responsible for Roche's Blockbuster Launch of Multiple Sclerosis Therapy Ocrevus® – NEW YORK, July 24, 2024 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the appointment of Simona Skerjanec, M.Pharm, MBA, a thought-leader in brain health with decades of experience in drug development and commercialization, to its board of directors, effective July 22, 2024. Over a nea

      7/24/24 6:30:00 AM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunic Appoints Jason Tardio as Chief Operating Officer and President

      – Former Novartis and Biogen Executive Brings Extensive Multiple Sclerosis Drug Commercialization Experience to Immunic – – Werner Gladdines, Current Vice President, Program Management & Clinical Development Operations, Promoted to Chief Development Officer – NEW YORK, July 9, 2024 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that seasoned biopharmaceutical executive, Jason Tardio, will be joining the company as Chief Operating Officer and President, effective July 12, 2024. In the newly created role, Mr. Tardio will lead in

      7/9/24 6:30:00 AM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care